At 68 weeks, participants taking 2.4 mg of semaglutide (Wegovy) weekly lost 15.8% of their body weight, compared to 6.4% for participants taking 3 mg of liraglutide (Saxenda)
In: Blau, N., Dionisi Vici, C., Ferreira, C.R., Vianey-Saban, C., van Karnebeek, C.D.M
Other safety considerations include: Potential interactions with SSRIs, benzodiazepines, or other psychiatric medications are not well studied Pregnant or breastfeeding individuals, and those with autoimmune or hormone-sensitive conditions, should avoid unsupervised use Medical supervision is essential, both to source a legitimate product and to monitor for adverse effects No peptide covered here is FDA-approved to treat anxiety or depression
When you receive your Blue Horizon report, it will clearly show where your levels fall in relation to the reference ranges
So much of the impact on weight in the US is based on the lifestyle choices we make and we know how hard it is to retrain your brain to develop healthier habits in a way that is easy, accessible and personalized